醒脑静注射液联合纤溶酶治疗急性脑梗死患者临床疗效分析

发布时间：2018-07-10 04:43

本文选题：急性脑梗死 + 治疗　；参考：《内科》2016年06期

【摘要】：目的探讨醒脑静注射液联合纤溶酶治疗急性脑梗死患者的临床疗效。方法选取2015年3月至2016年1月我院神经内科收治的急性脑梗死患者94例作为研究对象,采用随机数字表法分为实验组和对照组,每组47例,分别给予醒脑静注射液联合纤溶酶治疗和单纯纤溶酶治疗,比较两组患者的临床疗效,治疗前后NIHSS评分、ADL评分、TNF-α、IL-6炎症因子水平以及治疗过程不良反应发生情况。结果实验组患者的治疗总有效率(95.7%)显著高于对照组(76.6%),临床疗效显著优于对照组(P0.01)。治疗后两组患者NIHSS评分均显著下降、ADL评分均显著提高(P0.01),实验组患者NIHSS评分显著低于对照组、ADL评分显著高于对照组(P0.01);治疗后两组患者TNF-α、IL-6水平均显著降低(P0.05),实验组患者TNF-α、IL-6水平显著低于对照组(P0.05或0.01)。治疗过程中两组患者均无严重不良反应发生。结论与单纯采用纤溶酶治疗比较,醒脑静注射液联合纤溶酶治疗急性脑梗死能更有效地改善患者临床症状,减轻患者神经功能缺损,抑制炎症因子水平,提高患者生活能力,取得更好的临床治疗效果,值得推广应用。
[Abstract]:Objective to investigate the clinical effect of Xingnaojing injection combined with fibrinolytic enzyme on acute cerebral infarction. Methods from March 2015 to January 2016, 94 patients with acute cerebral infarction were randomly divided into experimental group (n = 47) and control group (n = 47). Xingnaojing injection combined with fibrinolytic enzyme therapy and simple plasminogen therapy were used to compare the clinical efficacy, NIHSS score and ADL score before and after treatment and the level of TNF- 伪 IL-6 inflammatory factor. Results the total effective rate (95.7%) of the patients in the experimental group was significantly higher than that of the control group (76.6%), and the clinical efficacy was significantly better than that of the control group (P0.01). After treatment, the scores of NIHSS in both groups decreased significantly (P0.01), the scores of NIHSS in the experimental group were significantly lower than those in the control group (P0.01), and the levels of TNF- 伪 IL-6 in the patients of the experimental group were significantly lower than those in the control group (P0.01), and the level of TNF- 伪 IL-6 in the experimental group was significantly lower than that in the control group (P0.05). The level of TNF- 伪 IL-6 was significantly lower than that of control group (P0.05 or 0.01). There were no serious adverse reactions in both groups. Conclusion compared with simple treatment with fibrinolytic enzyme, Xingnaojing injection combined with fibrinolytic enzyme can effectively improve the clinical symptoms of patients with acute cerebral infarction, reduce the neurological deficit, inhibit the level of inflammatory factors, and improve the living ability of patients with acute cerebral infarction. To obtain better clinical treatment effect, it is worth popularizing and applying.
【作者单位】：广东省惠州市中信惠州医院神经内科;
【分类号】：R743.33

【相似文献】